Takeda To Reclaim Sales Rights To Actos, Create Own Networks
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical plans to take back the sales rights to its key diabetes drug from Eli Lilly and create its own sales network in most of Europe, Canada and other countries outside Japan. Takeda already does its own selling of Actos (pioglitazone) in the United States, United Kingdom, France and other countries. Lilly had been marketing the drug in countries where Takeda lacked a sales network. Seven countries besides Canada are involved in the takeback--Belgium, Denmark, Luxembourg, Norway, Sweden and Turkey. (Click here for more - a subscription may be required